0
0
March 7, 2026
A new study has revealed a sharp decline in acetaminophen (Tylenol) prescriptions for pregnant women in U.S. emergency rooms following high-profile claims linking the common painkiller to autism risk. The research, published this week in The Lancet, found that hospital orders for the medication dropped by as much as 20% in the weeks following a September 2025 White House briefing where President Donald Trump labeled the drug “harmful” and urged expectant mothers to avoid it. The findings highlight the profound impact political rhetoric can have on clinical practice and patient behavior, even when contradicted by major medical authorities.
Sudden Shift in the Emergency Room
Researchers led by Dr. Jeremy Faust, an emergency physician at Brigham and Women’s Hospital and a faculty member at Harvard Medical School, analyzed electronic health records from over 1,600 U.S. hospitals. The data set covered more than 90,000 emergency department (ED) visits by pregnant women aged 15–44.
The study found an immediate 10% overall decrease in acetaminophen orders in the three months following the September 22, 2025, briefing. The decline was most pronounced in the third week after the statement, when orders plummeted by 16% to 20% compared to expected levels.
“It happened overnight,” Dr. Faust noted in a recent commentary. “This represents thousands of women potentially not receiving necessary pain control or fever reduction during a vulnerable time.”
While the study focused on hospital orders, it remains unclear whether the drop was driven by doctors hesitating to prescribe the drug or patients refusing it due to new fears. Interestingly, the researchers observed no change in Tylenol use among non-pregnant women, suggesting the shift was a direct response to the specific warning regarding prenatal exposure.
The Controversy: Political Claims vs. Scientific Consensus
The debate was reignited during the 2025 briefing when President Trump, joined by Health and Human Services (HHS) officials, claimed that Tylenol use during pregnancy drives rising autism rates. He cited unverified anecdotes and dismissed the lack of scientific consensus, prompting the FDA to initiate plans for revised labeling—a move that shocked many in the medical community.
Parallel to the Tylenol drop, the study documented a 71% surge in leucovorin prescriptions for children aged 5–17. Leucovorin, a B-vitamin variant typically used in cancer care, was promoted during the same briefing as a potential autism treatment. Prescriptions for the drug doubled in some weeks, despite what experts call “very limited and preliminary” evidence for its efficacy in treating autism symptoms.
“In an era where public confidence in health, medicine, and science is being challenged, it is unfortunate that so many families may have been misled,” Dr. Faust stated.
Navigating Mixed Evidence
The administration’s stance was not without some academic support. A August 2025 study from Mount Sinai, led by Dr. Diddier Prada, used a “Navigation Guide” methodology to suggest that higher-quality observational studies do point to a possible link between prenatal acetaminophen and neurodevelopmental risks like autism and ADHD.
“Given the widespread use of this medication, even a small increase in risk could have major public health implications,” Dr. Prada noted. He argued that biological mechanisms, such as oxidative stress or hormonal disruption, make a causal link plausible, though still unproven.
However, the broader scientific community has pushed back, citing more rigorous study designs. A landmark 2024 JAMA study of 2.5 million children in Sweden utilized a “sibling-control” design. By comparing siblings where one was exposed to Tylenol in utero and the other was not, researchers found the risk vanished. This suggests that the “link” found in other studies was likely due to shared genetics or the underlying reasons the mother took the drug (such as a severe infection or fever) rather than the drug itself.
Most recently, a January 2026 meta-analysis in The Lancet by Professor Asma Khalil of City St George’s, University of London, reviewed 43 high-quality studies and confirmed no clinically significant risk. “The message is clear—paracetamol [acetaminophen] remains a safe option during pregnancy when taken as guided,” Khalil said.
Public Health Implications
Medical organizations, including the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP), have been quick to reaffirm their guidelines. They warn that avoiding acetaminophen for high fevers can be more dangerous than the drug itself. Untreated maternal fever has been linked to neural tube defects and other developmental complications.
“More than 20 years of research have shown that acetaminophen is a safe, effective option,” ACOG stated in a formal rebuttal. “No high-quality evidence supports claims that it causes autism.”
For consumers, the takeaway is one of “judicious use.” Most experts, including those who lean toward caution like Harvard’s Andrea Baccarelli, advocate for using the lowest effective dose for the shortest possible duration.
Key Takeaways for Readers:
-
Consult Your Provider: Do not stop or change medications without speaking to your obstetrician.
-
Fever is a Risk: Untreated high fevers during pregnancy pose documented risks to fetal development.
-
Consider the Source: Distinguish between political statements and peer-reviewed, large-scale medical studies.
-
Short-Term Use: Acetaminophen remains the first-line recommendation for pain and fever when used as directed.
As research continues, the medical community faces the uphill task of rebuilding trust. While Tylenol orders began to stabilize by December 2025, the episode serves as a case study in how quickly public health behavior can shift in the face of high-level misinformation.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
